Brief: Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
08/08/2023 14:24
Aug 8 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA REACHES POSITIVE MILESTONE WITH NASAL
FORMULATION OF
SPC-15 FOR ANXIETY, PTSD, AND STRESS-RELATED DISORDERS
Source text for Eikon: ID:nGNX5DwTsd
Further company coverage: SILO.O
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement